title: Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia.
abstract: The influence of antipsychotic medication on brain morphology in schizophrenia may confound interpretation of brain changes over time. We aimed to assess the effect of discontinuation of atypical antipsychotic medication on change in brain volume in patients. Sixteen remitted, stable patients with first-episode schizophrenia, schizoaffective or schizophreniform disorder and 20 healthy controls were included. Two magnetic resonance imaging brain scans were obtained from all subjects with a 1-year interval. The patients either discontinued (n = 8) their atypical antipsychotic medication (olanzapine, risperidone, or quetiapine) or did not (n = 8) discontinue during the follow-up period. Intracranial volume and volumes of total brain, cerebral gray and white matter, cerebellum, third and lateral ventricle, nucleus caudatus, nucleus accumbens, and putamen were obtained. Multiple linear regression analyses were used to assess main effects for group (patient-control) and discontinuation (yes-no) for brain volume (change) while correcting for age, sex, and intracranial volume. Decrease in cerebral gray matter and caudate nucleus volume over time was significantly more pronounced in patients relative to controls. Our data suggest decreases in the nucleus accumbens and putamen volumes during the interval in patients who discontinued antipsychotic medication, whereas increases were found in patients who continued their antipsychotics. We confirmed earlier findings of excessive gray matter volume decrements in patients with schizophrenia compared with normal controls. We found evidence suggestive of decreasing volumes of the putamen and nucleus accumbens over time after discontinuation of medication. This might suggest that discontinuation reverses effects of atypical medication.
authors.affiliation: Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, The Netherlands. geartsje.boonstra@gmail.com
authors.forename: Geartsje
authors.initials: G
authors.lastname: Boonstra
authors.forename: Neeltje E M
authors.initials: NE
authors.lastname: van Haren
authors.forename: Hugo G
authors.initials: HG
authors.lastname: Schnack
authors.forename: Wiepke
authors.initials: W
authors.lastname: Cahn
authors.forename: Huibert
authors.initials: H
authors.lastname: Burger
authors.forename: Maria
authors.initials: M
authors.lastname: Boersma
authors.forename: Bart
authors.initials: B
authors.lastname: de Kroon
authors.forename: Diederick E
authors.initials: DE
authors.lastname: Grobbee
authors.forename: Hilleke E
authors.initials: HE
authors.lastname: Hulshoff Pol
authors.forename: René S
authors.initials: RS
authors.lastname: Kahn
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents